Latest Kestrel Therapeutics News & Updates

See the latest news and media coverage for Kestrel. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kestrel Therapeutics (Kestrel)

Biotechnology company developing KRAS-targeted cancer therapies

kestreltherapeutics.com

Headquarters: Watertown, United States
Founded year: 2020
Company type: Private company
Number of employees: 23–50
Industry: Biotechnology & Medical Research

Last updated September 15

Latest news about Kestrel Therapeutics (Kestrel)

In short: Kestrel received Fast Track status for KST-6051 and announced an AbbVie deal worth up to $1.45 billion

Company announcements

September 15 Kestrel

Kestrel receives FDA Fast Track designation for KST-6051

The designation applies to the pan-KRAS inhibitor treatment for advanced solid tumors in ongoing Phase 1 trials. This facilitates expedited review and frequent FDA communication.

April 29 Kestrel

Kestrel doses first patient in Phase 1 trial of KST-6051 KRAS inhibitor

The company also announced a strategic warrant agreement with AbbVie for up to $1.45 billion, including an exclusive acquisition option.

March 5 Kestrel

Kestrel announces FDA IND clearance for KST-6051

The Phase 1 trial FALCON will enroll patients with advanced KRAS-mutant solid tumors.

April 17, 2025 Kestrel

Kestrel welcomes Ron Knickerbocker as new SVP of Data Sciences and Clinical Development

He brings extensive experience to the role, strengthening the Clinical Development team's capabilities.

Media coverage

September 15 BioSpace

Kestrel Therapeutics Receives FDA Fast Track Designation for KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in the treatment of KRAS-Mutant Advanced Solid Tumors - BioSpace

WATERTOWN, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical-stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant...

March 5 MENAFN

Kestrel Therapeutics Announces First Patient Dosed In The Phase 1 Clinical Trial Of KST-6051, A Potential Best-In-Class Pan-KRAS Inhibitor, In Patients With KRAS-Driven ...

(MENAFN- GlobeNewsWire - Nasdaq) Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on...

Never miss news about Kestrel

Track Kestrel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.